BACKGROUND AND OBJECTIVES: For patients with advanced cancers, it is important that treatment improves the quality as well as the quantity of survival. This quality-adjusted time without symptoms of progression or toxicity (Q-TWiST) analysis provides a combined measure of both the overall survival interval and the quality of survival for patients with advanced renal cell carcinoma (RCC) receivingtemsirolimus, interferon (IFN)-alpha or the combination of these agents, using data from a phase III clinical trial. METHODS:Overall survival was partitioned into three distinct health states: time with serious toxicity (TOX), time after progression (REL) and time without symptoms of progression or toxicity (TWiST). Health states were quality weighted by patient-reported EQ-5D measures collected while receiving treatment. RESULTS:All 626 patients from the trial were included in computation of health-state durations. EQ-5D questionnaires were obtained from 260 patients upon progression and from 230 after a grade 3 or 4 adverse event, and from 278 patients in the TWiST state. Patients receiving temsirolimus had 38% longer TWiST than those receiving IFNalpha (6.5 vs 4.7 months, respectively; p = 0.0005). Patients receiving temsirolimus had 25% longer quality-adjusted survival in terms of Q-TWiST than those receiving IFNalpha (7.0 vs 5.6 months, respectively; p = 0.0015). Differences between the combination (temsirolimus + IFNalpha) and IFNalpha groups were not statistically significant. Threshold utility analysis indicated that temsirolimus was the preferred alternative for all possible utility weights for REL and TOX health states. CONCLUSION: Temsirolimus resulted in significantly longer Q-TWiST (quality-adjusted survival) in patients with advanced RCC than IFNalpha therapy.
RCT Entities:
BACKGROUND AND OBJECTIVES: For patients with advanced cancers, it is important that treatment improves the quality as well as the quantity of survival. This quality-adjusted time without symptoms of progression or toxicity (Q-TWiST) analysis provides a combined measure of both the overall survival interval and the quality of survival for patients with advanced renal cell carcinoma (RCC) receiving temsirolimus, interferon (IFN)-alpha or the combination of these agents, using data from a phase III clinical trial. METHODS: Overall survival was partitioned into three distinct health states: time with serious toxicity (TOX), time after progression (REL) and time without symptoms of progression or toxicity (TWiST). Health states were quality weighted by patient-reported EQ-5D measures collected while receiving treatment. RESULTS: All 626 patients from the trial were included in computation of health-state durations. EQ-5D questionnaires were obtained from 260 patients upon progression and from 230 after a grade 3 or 4 adverse event, and from 278 patients in the TWiST state. Patients receiving temsirolimus had 38% longer TWiST than those receiving IFNalpha (6.5 vs 4.7 months, respectively; p = 0.0005). Patients receiving temsirolimus had 25% longer quality-adjusted survival in terms of Q-TWiST than those receiving IFNalpha (7.0 vs 5.6 months, respectively; p = 0.0015). Differences between the combination (temsirolimus + IFNalpha) and IFNalpha groups were not statistically significant. Threshold utility analysis indicated that temsirolimus was the preferred alternative for all possible utility weights for REL and TOX health states. CONCLUSION:Temsirolimus resulted in significantly longer Q-TWiST (quality-adjusted survival) in patients with advanced RCC than IFNalpha therapy.
Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: David F McDermott; Meredith M Regan; Joseph I Clark; Lawrence E Flaherty; Geoffery R Weiss; Theodore F Logan; John M Kirkwood; Michael S Gordon; Jeffrey A Sosman; Marc S Ernstoff; Christopher P G Tretter; Walter J Urba; John W Smith; Kim A Margolin; James W Mier; Jared A Gollob; Janice P Dutcher; Michael B Atkins Journal: J Clin Oncol Date: 2005-01-01 Impact factor: 44.544
Authors: Gary Hudes; Michael Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer Journal: N Engl J Med Date: 2007-05-31 Impact factor: 91.245
Authors: Luciana Schultz; Alcides Chaux; Roula Albadine; Jessica Hicks; Jenny J Kim; Angelo M De Marzo; Mohamad E Allaf; Michael A Carducci; Ronald Rodriguez; Hans-Joerg Hammers; Pedram Argani; Victor E Reuter; George J Netto Journal: Am J Surg Pathol Date: 2011-10 Impact factor: 6.394
Authors: David F McDermott; Ruchit Shah; Komal Gupte-Singh; Javier Sabater; Linlin Luo; Marc Botteman; Sumati Rao; Meredith M Regan; Michael Atkins Journal: Qual Life Res Date: 2018-09-06 Impact factor: 4.147
Authors: Elisa Zanardi; Elena Verzoni; Paolo Grassi; Andrea Necchi; Patrizia Giannatempo; Daniele Raggi; Filippo De Braud; Giuseppe Procopio Journal: Ther Adv Urol Date: 2015-06
Authors: S Patil; R A Figlin; T E Hutson; M D Michaelson; S Negrier; S T Kim; X Huang; R J Motzer Journal: Br J Cancer Date: 2012-05-08 Impact factor: 7.640